# US 2017/0281776 A1 · Steroid hormone compositions in medium chain oils

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281776 A1
- Document ID: US20170281776A1
- Status: Published application
- Kind: A1
- Application number: 15/473,742
- Filed: 2017-03-30
- Published: 2017-10-05
- Earliest claimed: 2016-04-01
- Assignees: TherapeuticsMD, Inc.
- Applicants: TherapeuticsMD, Inc.
- Inventors: Annette SHADIACK; Peter H.R. PERSICANER; Philip B. INSKEEP; Thorsteinn THORSTEINSSON; Frederick D. SANCILIO; Jason D. LEGASSIE
- Web page: https://patentgrep.com/patent/US20170281776A1

## CPC

- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/145: {with organic compounds}
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61P 5/00: Drugs for disorders of the endocrine system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides a novel pharmaceutical composition capable of forming micelles upon exposure to the gastric environment. The pharmaceutical composition is suitable for delivering steroid hormones, and progesterone in particular, to a subject in need thereof

## Claims

### Claim 1

A pharmaceutical composition for providing enhanced oral bioavailability of progesterone, the pharmaceutical composition comprising:
progesterone, a polysorbate, and a medium chain oil, wherein
the medium chain oil comprises at least about 50 weight percent of a
predominantly medium chain monoglyceride; and
the progesterone is fully solubilized.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the medium chain oil comprises at least about 70 weight percent of a predominantly medium chain monoglyceride.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, and polysorbate 80.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition provides an oral bioavailability of at least about 150 percent as measured by an increase in AUC when compared to a reference product.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, further comprising at least one of a polyoxyethylene hydrogenated castor oil, a D-α-Tocopherol polyethylene glycol succinate derivative, or a terpene.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the predominantly medium chain monoglyceride and the progesterone can be present at a weight ratio of about 10:1 to about 15:1.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the predominantly medium chain monoglyceride comprises at least about 90 weight percent of the medium chain oil.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, and polysorbate 80.

### Claim 9 (depends on 6)

The pharmaceutical composition of claim 6, wherein the pharmaceutical composition provides an oral bioavailability of at least about 150 percent as measured by an increase in AUC when compared to a reference product.

### Claim 10 (depends on 6)

The pharmaceutical composition of claim 6, further comprising at least one of a polyoxyethylene hydrogenated castor oil, d-α-tocopherol polyethylene glycol succinate derivative, or a terpene.

### Claim 11

An oral, fully-solubilized progesterone pharmaceutical composition comprising:
progesterone and a polysorbate in a weight ratio of from about 1:2 to about 2:1; and
a medium chain oil comprising a mixture of medium chain mono- and diglycerides, the medium chain oil not containing more than about 10 weight percent triglycerides.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, and polysorbate 80.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the pharmaceutical composition provides an oral bioavailability of at least about 150 percent as measured by an increase in AUC when compared to a reference product.

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11, further comprising at least one of a polyoxyethylene hydrogenated castor oil, a d-α-tocopherol polyethylene glycol succinate derivative, or a terpene.

### Claim 15 (depends on 1)

A method of treating a disease or condition associated with reduced progesterone levels, the method comprising administering to a subject in need thereof a pharmaceutical composition according to claim 1.

### Claim 16 (depends on 11)

A method of treating a disease or condition associated with reduced progesterone levels, the method comprising administering to a subject in need thereof a pharmaceutical composition according to claim 11.

### Claim 17 (depends on 15)

The method of claim 15, wherein the disease or condition associated with reduced progesterone levels is selected from the group consisting of menopause, endometrial hyperplasia; secondary amenorrhea; prevention of preterm birth; and osteoporosis.

### Claim 18 (depends on 16)

The method of claim 16, wherein the disease or condition associated with reduced progesterone levels is selected from the group consisting of menopause, endometrial hyperplasia; secondary amenorrhea; prevention of preterm birth; and osteoporosis.

### Claim 19

A pharmaceutical composition for providing enhanced oral bioavailability of progesterone, the pharmaceutical composition comprising:
progesterone, a polysorbate, and a medium chain oil, wherein
the medium chain oil comprises at least about 50 weight percent of a first medium chain oil component; and
the progesterone is fully solubilized.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the medium chain oil further comprises a second medium chain oil component and wherein the first medium chain oil component is a predominantly medium chain monoglyceride and wherein the second medium chain oil component is a predominantly medium chain diglyceride.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20, wherein the predominantly medium chain diglyceride is a mixed or complex diglyceride.
